GLP1
-
Next-gen anti-obesity drugs like injectable liraglutide, sold as Saxenda, deliver impressive results in the first 12 months. New research looks into what happens to those results once treatment stops.
-
In yet another surprise attribute of the new class of obesity drugs, scientists have found that GLP-1 receptor agonists can also subdue brain inflammation, giving them a potential ‘superpower’ in the fight against Alzheimer’s and Parkinson’s diseases.
-
Scientists have found that linking two hormones into a single molecule has the potential for improving the treatment of metabolic disorders such as type 2 diabetes and obesity.